SB 764

  • Oregon Senate Bill
  • 2021 Regular Session
  • Introduced in Senate Feb 18, 2021
  • Senate
  • House
  • Governor

Relating to agreements that lead to anticompetitive behavior in the market for pharmaceutical drugs; prescribing an effective date.

Abstract

Provides that Attorney General and court must presume that resolution agreement that ends dispute over alleged infringement of patent or violation of other protection for protected drug has anticompetitive effects if alleged infringer receives item of value as part of or in connection with resolution agreement or if alleged infringer agrees to limit or stop researching, developing, manufacturing, marketing or selling competing drug. Specifies basis on which party to resolution agreement may overcome presumption. Provides that Attorney General may bring action to recover civil penalty for violations of Act in amount that is equivalent to three times value of item of value that alleged infringer received or $10 million, whichever is greater. Takes effect on 91st day following adjournment sine die.

Bill Sponsors (16)

Votes


Actions


Apr 07, 2021

Senate

Work Session held.

Mar 03, 2021

Senate

Public Hearing held.

Feb 22, 2021

Senate

Referred to Health Care.

Feb 18, 2021

Senate

Introduction and first reading. Referred to President's desk.

Bill Text

Bill Text Versions Format
Introduced PDF
SHC Amendment -2 PDF

Related Documents

Document Format
No related documents.

Sources

Data on Open States is updated nightly from the official website of the Oregon Legislative Assembly.

If you notice any inconsistencies with these official sources, feel free to file an issue.